Candel Therapeutics, Inc. 8-K

What Happened

• On March 12, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter and full year ended December 31, 2025. The company furnished a press release with the results as Exhibit 99.1 to this Current Report on Form 8-K. The filing notes the furnished information is not “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings. The report is signed by CEO Paul Peter Tak, M.D., Ph.D.

Key Details

• Event date: March 12, 2026 (8-K filing announcing results).
• Reporting periods: quarter and year ended December 31, 2025.
• Disclosure format: press release furnished as Exhibit 99.1 to the Form 8-K.
• Legal note: information furnished (not “filed”) under the Exchange Act; limits Section 18 liabilities.

Why It Matters

• This 8-K signals that Candel has released its latest quarterly and full‑year financial results (earnings/revenue and other operating metrics) — investors should read the Exhibit 99.1 press release for the actual figures and any commentary on revenue, profit/loss, cash position, or guidance.
• Because the release is furnished rather than filed, it’s provided for disclosure but is not subject to certain liability provisions and isn’t automatically incorporated into other SEC filings.
• Retail investors tracking Candel’s earnings, revenue trends, or upcoming catalysts should review the press release and any subsequent SEC filings (e.g., 10-Q/10-K) for full financial detail and context.